Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748287 · ClinicalTrials.gov registry record · Early Phase 1
A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia
A Early Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 104
- Enrollment target
NCT06748287 is a Early Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 104 participants.
The verdict
NCT06748287, a Early Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
Photobiomodulation is a form of non-ionizing light therapy has been shown to stimulate cellular processes and reduce inflammation as well as improve pain and wound healing. Photobiomodulation has also been found to enhance fibroblast growth factor production. A challenge in clinic is to answer the patients' questions regarding which FDA-cleared device is the best to purchase. Therefore, this study was designed to gain experience with the use of the following devices and to clinically evaluate their efficacy: iGrow Hair Growth System, Capillus352, Hair Max Ultima 12 LaserComb, and HairMax Laserband 82. The purpose of this pilot research study is to clinically compare and evaluate FDA-cleared photobiomodulation devices after four months of treatment and one-month follow-up in subjects with alopecia.
Interventions
- DEVICE iGrow Hair Growth System
- DEVICE Capillus352
- DEVICE HairMax Ultima 12 Lasercomb
- DEVICE HairMax Laserband 82
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2017-01-03 |
| Est. Completion | 2023-02-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06748287
The ClinicalTrials.gov registry entry for NCT06748287 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which iGrow Hair Growth System is the first listed.
NCT06748287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06748287 about?
NCT06748287 is a clinical study titled "A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia". Photobiomodulation is a form of non-ionizing light therapy has been shown to stimulate cellular processes and reduce inflammation as well as improve pain and wound healing. Photobiomodulation has also been found to enhance fibroblast growth factor production. A challenge in clinic is to answer the p...
What is the current status of trial NCT06748287?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 104 participants. The study started on 2017-01-03. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT06748287?
The interventions under investigation include: iGrow Hair Growth System (DEVICE), Capillus352 (DEVICE), HairMax Ultima 12 Lasercomb (DEVICE), HairMax Laserband 82 (DEVICE).
Who is sponsoring clinical trial NCT06748287?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.